Mateon Therapeutics Inc. buy klostergang
Start price
03.06.15
/
50%
€1.36
Target price
07.12.15
€1.70
Performance (%)
-39.82%
End price
07.12.15
€0.82
Summary
This prediction ended on 07.12.15 with a price of €0.82. The BUY prediction by klostergang for Mateon Therapeutics Inc. performed very badly with a performance of -39.82%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Mateon Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | -1.862% | -1.624% | 0.645% | 51.035% |
| iShares Nasdaq 100 | -3.322% | 3.321% | 32.004% | 86.512% |
| iShares Nikkei 225® | -2.299% | 3.437% | 51.012% | 58.809% |
| iShares S&P 500 | -1.313% | 2.435% | 23.006% | 65.411% |
Comments by klostergang for this prediction
In the thread Mateon Therapeutics Inc. diskutieren
Die FDA billigt PFS als primären Endpunkt der Phase-3-Studie :
http://seekingalpha.com/article/3228966-there-is-significant-upside-ahead-for-oxigene
(Vom Mitglied beendet)